Lisa Rojkjaer - 27 Mar 2024 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role
EVP, Chief Medical Officer
Signature
/s/ Raymond Furey (Attorney-in-Fact)
Issuer symbol
RIGL
Transactions as of
27 Mar 2024
Net transactions value
$0
Form type
4
Filing time
29 Mar 2024, 16:09:32 UTC
Previous filing
17 Mar 2023
Next filing
31 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RIGL Employee Stock Option (right to buy) Award $0 +187,500 $0.000000 187,500 27 Mar 2024 Common Stock 187,500 $1.49 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth (1/4th) of the shares subject to this option vest on March 11, 2025, and 1/48th of the shares subject to this option vest in substantially equal monthly installments over the thirty-six (36) months thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.